A cost-utility analysis of different antiviral medicine regimens in patients with chronic hepatitis C virus genotype 1 infection
Joint Authors
Sanati, Ihsan
Keshavarz, Khosro
Hemami, Muhsin Rezaei
Nikfar, Shekoufeh
Lutfi, Farhad
Alavian, Sayyid Muayyad
Source
Iranian Red Crescent Medical Journal
Issue
Vol. 18, Issue 11 (30 Nov. 2016), pp.1-10, 10 p.
Publisher
Publication Date
2016-11-30
Country of Publication
United Arab Emirates
No. of Pages
10
Main Subjects
Pharmacy, Health & Medical Sciences
Abstract EN
Background : Despite the introduction of new drug regimens with high effectiveness for the hepatitis C virus (HCV) patients, especially in HCV genotype 1, no cost-effectiveness study on the selection of the superior drug strategy in Iran has been conducted yet.
Objectives : This study is aimed to assess the cost-effectiveness of the three drug regimens of pegylated interferon and ribavirin (PR), sofosbuvir (SOF) + PR and ledipasvir and sofosbuvir (LDV/SOF) in patients with HCV genotype 1 in Iran in the year 2014.
Methods : A Markov micro-simulation model was used to evaluate the cost-effectiveness of the three drug strategies for a cohort of 10000 patients.
Quality-adjusted life-years (QALYs) were extracted from published studies.
Cost data was estimated through the review of medical records and obtaining experts opinion.
Results : The results showed that the SOF + PR drug compared with PR had a lower cost and was more effective, but compared with the LDV/SOF, in spite of its lower cost, it was less efficient.
The QALY values obtained for PR, SOF + PR and LDV/SOF, respectively, were 10.98, 12.08 and 12.28 and their costs were $ 41,741, $ 7,676 and $ 46,993.
Moreover, the results obtained from acceptability curves showed that SOF + PR were the most cost-effective treatment for thresholds below $ 45,270 PPP.
Conclusions : The use of SOF + PR regimen or LDV/SOF can significantly reduce the incidence of complications associated with the disease.
For example, short and long-term outcomes are better than the current drug regimens for HCV genotype 1 patients in all stages of the disease.
American Psychological Association (APA)
Alavian, Sayyid Muayyad& Nikfar, Shekoufeh& Kebriaeezadeh, Abbas& Lutfi, Farhad& Sanati, Ihsan& Hemami, Muhsin Rezaei…[et al.]. 2016. A cost-utility analysis of different antiviral medicine regimens in patients with chronic hepatitis C virus genotype 1 infection. Iranian Red Crescent Medical Journal،Vol. 18, no. 11, pp.1-10.
https://search.emarefa.net/detail/BIM-728760
Modern Language Association (MLA)
Kebriaeezadeh, Abbas…[et al.]. A cost-utility analysis of different antiviral medicine regimens in patients with chronic hepatitis C virus genotype 1 infection. Iranian Red Crescent Medical Journal Vol. 18, no. 11 (Nov. 2016), pp.1-10.
https://search.emarefa.net/detail/BIM-728760
American Medical Association (AMA)
Alavian, Sayyid Muayyad& Nikfar, Shekoufeh& Kebriaeezadeh, Abbas& Lutfi, Farhad& Sanati, Ihsan& Hemami, Muhsin Rezaei…[et al.]. A cost-utility analysis of different antiviral medicine regimens in patients with chronic hepatitis C virus genotype 1 infection. Iranian Red Crescent Medical Journal. 2016. Vol. 18, no. 11, pp.1-10.
https://search.emarefa.net/detail/BIM-728760
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references : p. 9-10
Record ID
BIM-728760